Pyxis Oncology Investor Relations Material

Pyxis Oncology Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer. It is focused on helping patients with cancer through a differentiated portfolio of biologics, specifically targeting tumor cells and overcoming immune suppression. Pyxis Oncology's strategy encompasses the use of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, aiming to improve outcomes for patients with difficult-to-treat cancers. The company is headquartered in Boston, MA, and its shares are listed on the Nasdaq.